ARDT Stock Forecast & Price Target

Ardent Health Inc. has demonstrated strong financial growth, with EBITDA increasing by 46% year-over-year to $143 million, alongside an improved margin of 9.1%, which reflects a 240 basis point increase. The company has also seen a 2.9% rise in admissions, aligning with its full-year outlook, while professional fees rose by 11%, emphasizing the resilience of revenue streams from critical services like anesthesia and radiology. Furthermore, positive trends in the hospital sector and the potential for advancements in Ardent’s outpatient strategy indicate significant growth opportunities, suggesting that the company is currently under-earning in relation to its potential.

Ardent Health's stock outlook appears negative due to several fundamental concerns, including a disappointing EBITDA performance of $143 million, which was 2% below expectations and significantly impacted by a temporary boost from Kansas Statewide Disproportionate Share Payments. The company faces challenges related to its revenue management transition, which resulted in a $43 million revenue adjustment and suggests increased uncertainty regarding accounts receivable collectability. Additionally, lowered EBITDA-NCI estimates for 2025 and 2026, now at $542 million and $536 million respectively, indicate a downward revision that reflects persistent headwinds from denial rates and professional fee collections, leading to expectations of minimal or negative EBITDA growth moving forward.